机译:Erlotinib用于治疗复发/难治性急性髓性白血病患者的试验期II研究
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Experimental Therapeutics The University of Texas MD Anderson Cancer Center Houston;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA;
Erlotinib; Acute myeloid leukemia; Relapsed/refractory AML;
机译:Erlotinib用于治疗复发/难治性急性髓性白血病患者的试验期II研究
机译:阶段1剂量升级对口服eBEXINOSTAT用于治疗复发/难治性更高风险的髓细胞增强综合征,急性髓性白血病或急性淋巴细胞白血病患者
机译:校正:与氟拉西滨,含紫花霉素,糖醇和G-CSF(Pleriflag方案)组合的Plerixafor的I-II研究用于治疗患者的第一个早期复发或难治性急性髓性白血病
机译:计算源自骨髓移植后急性髓性白血病患者复发风险的细胞学图像标志物
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:试验期II研究中硫酸盐脂质体注射液在复发或难治性急性髓性白血病患者中的可行性和功效研究
机译:Erlotinib用于治疗复发/难治性急性髓性白血病患者的试验期II研究